Navigation Links
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Date:11/15/2012

them," said Andreas Koester, MD, PhD, Head, Clinical Trial Innovation/External Alliances, Janssen Research & Development. "We are enthusiastic about working with other industry leaders to collectively apply our expertise, capabilities and shared passion for advancing science and improving lives." 

Earlier this year, Janssen joined nine other companies to launch TransCelerate BioPharma Inc. ("TransCelerate"), the largest initiative of its kind, which aims to identify and overcome common drug development challenges in order to improve the quality of clinical studies and to bring new medicines to patients faster. The initiative identified the centralization of site prequalification and training as one of five key projects, and the Janssen-led Investigator Databank project will serve as a foundation for the TransCelerate initiative.

"Industry collaboration, including pre-competitive data sharing, is critical to ensuring continued progress to improve industry-wide clinical trial practices," said newly appointed CEO of TransCelerate BioPharma, Garry Neil, MD, Partner at Apple Tree Partners and formerly Corporate Vice President, Science & Technology, Johnson & Johnson. "This work is aligned with TransCelerate's initial focus on clinical study execution and we encourage participation from our founding TransCelerate companies to solve industry-wide challenges in a collaborative environment." 

Member companies of TransCelerate who wish to join the Investigator Databank will automatically qualify for participation. It is anticipated that the Investigator Databank will be operational by the end of the year and incorporated into one of the priority projects within TransCelerate by mid-2013.

The Investigator Databank will be hosted by DrugDev.org, an independent, third pa
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today announced ... shares of its common stock at a price to ... to Tandem from this offering are expected to be ... other estimated offering expenses payable by Tandem. All of ...
(Date:2/26/2015)... BEND, Ind. , Feb. 26, 2015  Mobility ... announce an agreement with Bank of America (NYSE: ... consumers nationwide to receive financing of the revolutionary MV-1 ... vehicle, designed from the ground up to provide safe ... Approved applicants can use their loan to purchase a ...
Breaking Medicine Technology:Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... Reportlinker.com announces that a new market research report ... Sanofi-Aventis: PharmaVitae Profile http://www.reportlinker.com/p0201760/Sanofi-Aventis-PharmaVitae-Profile.html ... examines the historical and forecast performance for Sanofi-Aventis ... company strategy, portfolio and pipeline analysis and assessment ...
... As technologies for fat removal become more advanced, physicians ... the body but also recycling the fat to further ... recent statistics from the American Society for Aesthetic Plastic ... two most popular invasive and non-invasive cosmetic procedures in ...
Cached Medicine Technology:Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 2Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 3Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 4Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 5Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 6Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile 7The New Face of Body Contouring 2
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 With their ... Fitness has added an additional exercise to their already ... oblique exercise is most commonly known as, is often ... “Rope Pulls” are executed in a relatively safe manner ... and strength levels. The full description of “Rope Pulls” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Mew and ... announced that they now provide business consulting services in ... as corporate tax planning and succession planning. Company finances ... to experienced professionals. On top of this, complex Canadian ... handle corporate accounting. As a result, Mew and Company ...
(Date:2/28/2015)... 28, 2015 For those people who ... the Mesothelioma Applied Research Foundation (Meso Foundation) ... March 3, starting at 9:30 AM. , The live ... The broadcast can be accessed through any browser on ... , The Symposium is a unique event that covers ...
(Date:2/28/2015)... Pismo Beach, CA (PRWEB) February 28, 2015 ... the needs of Central Coast area residents, recently announced ... Whitening System. It’s a treatment option for new ... patients kick off 2015 with a bright, white smile, ... the discounted price of $299, marked down from the ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... Cardiva Medical, Inc. announced today that it has received ... for its latest technology, the Cardiva Catalyst III, which ... in the market. Built upon its predecessor, the ... which neutralizes heparin in the tissue adjacent to the ...
... 19 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... aesthetics, dermatology, environmental and nutraceutical products, today announced that ... Tuesday, June 2, 2009 at 4:30 PM Eastern Time. ... (U.S.) and 1-201-689-8471 (international). The call will also ...
... (www.meettheburns.com) targets first time athlete,s foot sufferers and ... Schering-Plough Corporation (NYSE: SGP ) ... antifungal spray for the treatment of athlete,s foot. ... spray and deodorant powder spray.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/NY19030 ...
... profile "New Strategies for Optimizing CHO Performance" inside the BIO Process ... ... Fort Collins, CO (PRWEB) May 19, 2009 -- Amidst ... International Convention will be InVitria, a cell culture media supplement company ...
... patient with help from GI specialists, GI Monitor, an ... (IBD) Crohn,s and Ulcerative Colitis to track their symptoms ... N.J., May 19 WellApps, Inc. launched an iPhone ... Colitis provide accurate symptom data to their doctors for ...
... May 19 Regulatory processes differ across continents, ... pressing need to integrate the regulatory environment of ... regulations impact drug launches as less price controlled ... in regulated markets. The pharmaceutical industry, along with ...
Cached Medicine News:Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 2Health News:Cardiva Medical, Inc. Receives FDA Clearance for the Catalyst(TM)III System, First in Class Drug Coated Vessel Closure Device 3Health News:Nuvilex, Inc. Announces Monthly Investor Conference Call 2Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:InVitria to Present at BIO 2009 International Convention in Atlanta 2Health News:IBD Patient Launches iPhone Application to Help Doctors Treat Crohn's and Ulcerative Colitis 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4
... PC captures, displays, replays and analyzes ... proven to be effective in evaluating ... obstructive pulmonary disease.,It provides objective evidence ... , , Waveform and time-expanded ...
... Acoustic Cardioscan Viewer Phonocardiogram (PCG). The ... allows you to record, condition, display and ... stethoscope. The product acquires and displays ... to four sites, and allows user-selectable filtering ...
... The MULTIVIEW WORKSTATION enhances patient ... access, rapid assessment, decision support, and ... hospital. Part of the INFINITY Patient ... comprehensive patient information, including continuous, real-time ...
... The biograph 16 offers the ... disease diagnosis and treatment in ... delivers high-quality PET/CT whole body ... minutes. Our comprehensive suite of ...
Medicine Products: